{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T02:09:42Z","timestamp":1776910182580,"version":"3.51.2"},"reference-count":43,"publisher":"Europa Digital & Publishing","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["EuroIntervention"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.4244\/eijv9i3a53","type":"journal-article","created":{"date-parts":[[2013,9,12]],"date-time":"2013-09-12T13:13:27Z","timestamp":1378991607000},"page":"316-327","source":"Crossref","is-referenced-by-count":36,"title":["The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation"],"prefix":"10.4244","volume":"9","author":[{"given":"Zhen-Yang","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Ling","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Hui","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2774","reference":[{"key":"key-201381784832-0","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","article-title":"Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.","volume":"373","author":"Baigent C.","year":"2009","journal-title":"Lancet."},{"key":"key-201381784832-1","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(96)09457-3","article-title":"A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.","volume":"348","author":"CAPRIE Steering Committee.","year":"1996","journal-title":"Lancet."},{"key":"key-201381784832-2","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.","volume":"345","author":"Yusuf S.","year":"2001","journal-title":"N Engl J Med."},{"key":"key-201381784832-3","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1016\/j.jacc.2011.02.009","article-title":"2011 ACCF\/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina\/Non-ST-Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons.","volume":"57","author":"Wright RS.","year":"2011","journal-title":"J Am Coll Cardiol."},{"key":"key-201381784832-4","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1161\/CIRCULATIONAHA.107.188208","article-title":"2007 Focused Update of the ACC\/AHA\/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC\/AHA\/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee.","volume":"117","author":"King SB 3rd.","year":"2008","journal-title":"Circulation."},{"key":"key-201381784832-5","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/j.jacc.2006.11.044","article-title":"Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives.","volume":"49","author":"Angiolillo DJ.","year":"2007","journal-title":"J Am Coll Cardiol."},{"key":"key-201381784832-6","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1124\/dmd.109.028498","article-title":"A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel.","volume":"37","author":"Hagihara K.","year":"2009","journal-title":"Drug Metab Dispos."},{"key":"key-201381784832-7","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1124\/dmd.109.029132","article-title":"Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite.","volume":"38","author":"Kazui M.","year":"2010","journal-title":"Drug Metab Dispos."},{"key":"key-201381784832-8","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1055\/s-0037-1614133","article-title":"Identification and biological activity of the active metabolite of clopidogrel.","volume":"84","author":"Savi P.","year":"2000","journal-title":"Thromb Haemost."},{"key":"key-201381784832-9","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1503\/cmaj.060664","article-title":"Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel.","volume":"174","author":"Suh JW.","year":"2006","journal-title":"CMAJ."},{"key":"key-201381784832-10","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa0809171","article-title":"Cytochrome p-450 polymorphisms and response to clopidogrel.","volume":"360","author":"Mega JL.","year":"2009","journal-title":"N Engl J Med."},{"key":"key-201381784832-11","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1161\/01.CIR.0000085073.69189.88","article-title":"Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects.","volume":"108","author":"Fontana P.","year":"2003","journal-title":"Circulation."},{"key":"key-201381784832-12","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1016\/S0140-6736(10)61273-1","article-title":"Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.","volume":"376","author":"Mega JL.","year":"2010","journal-title":"Lancet."},{"key":"key-201381784832-13","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.clpt.2006.07.007","article-title":"Impact of P-glycoprotein on clopidogrel absorption.","volume":"80","author":"Taubert D.","year":"2006","journal-title":"Clin Pharmacol Ther."},{"key":"key-201381784832-14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/1753944707087409","article-title":"The new European Society of Hypertension\/European Society of Cardiology (ESH\/ESC) Guidelines.","volume":"2","author":"Mancia G.","year":"2008","journal-title":"Ther Adv Cardiovasc Dis."},{"key":"key-201381784832-15","first-page":"160","article-title":"Summary of the third report of the National Cholesterol Education Program Adult Treatment Panel III.","volume":"2","author":"Lepor NE.","year":"2001","journal-title":"Rev Cardiovasc Med."},{"key":"key-201381784832-16","first-page":"113","article-title":"Screening and diagnosis of gestational diabetes. Evaluation of the methodological quality of the guidelines of the Haute Autorite de Sante, of the American Diabetes Association, and of the World Health Organisation.","volume":"68","author":"Augereau C.","year":"2010","journal-title":"Ann Biol Clin (Paris)."},{"key":"key-201381784832-17","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.jacc.2007.02.013","article-title":"ACC\/AHA 2007 guidelines for the management of patients with unstable angina\/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina\/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine.","volume":"50","author":"Anderson JL.","year":"2007","journal-title":"J Am Coll Cardiol."},{"key":"key-201381784832-18","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions.","volume":"115","author":"Cutlip DE.","year":"2007","journal-title":"Circulation."},{"key":"key-201381784832-19","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1016\/j.jacc.2009.10.015","article-title":"2009 focused updates: ACC\/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC\/AHA\/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines.","volume":"54","author":"Kushner FG.","year":"2009","journal-title":"J Am Coll Cardiol."},{"key":"key-201381784832-20","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1136\/hrt.2010.220491","article-title":"High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention.","volume":"97","author":"Breet NJ.","year":"2011","journal-title":"Heart."},{"key":"key-201381784832-21","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1160\/TH09-06-0418","article-title":"Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis.","volume":"103","author":"Sofi F.","year":"2010","journal-title":"Thromb Haemost."},{"key":"key-201381784832-22","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.jacc.2010.04.047","article-title":"Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.","volume":"56","author":"Bonello L.","year":"2010","journal-title":"J Am Coll Cardiol."},{"key":"key-201381784832-23","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1080\/09537100802351065","article-title":"Platelet reactivity to adenosine diphosphate and long-term ischemic event occurrence following percutaneous coronary intervention: a potential antiplatelet therapeutic target.","volume":"19","author":"Gurbel PA.","year":"2008","journal-title":"Platelets."},{"key":"key-201381784832-24","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.ahj.2010.06.004","article-title":"Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis.","volume":"160","author":"Aradi D.","year":"2010","journal-title":"Am Heart J."},{"key":"key-201381784832-25","article-title":"Personalized antiplatelet treatment after percutaneous coronary intervention: The MADONNA study.","volume":"Epub AOP","author":"Siller-Matula JM.","year":"2012 May 30.","journal-title":"Int J Cardiol."},{"key":"key-201381784832-26","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1056\/NEJMoa1209979","article-title":"Bedside monitoring to adjust antiplatelet therapy for coronary stenting.","volume":"367","author":"Collet JP","year":"2012","journal-title":"N Engl J Med."},{"key":"key-201381784832-27","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.jcin.2012.07.015","article-title":"CYP2C19*2 and *17 alleles have a significant impact on platelet response and bleeding risk in patients treated with prasugrel after acute coronary syndrome.","volume":"5","author":"Cuisset T.","year":"2012","journal-title":"JACC Cardiovasc Interv."},{"key":"key-201381784832-28","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1111\/j.1538-7836.2007.02775.x","article-title":"Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.","volume":"5","author":"Brandt JT.","year":"2007","journal-title":"J Thromb Haemost."},{"key":"key-201381784832-29","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/clpt.2008.20","article-title":"The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance.","volume":"84","author":"Kim KA.","year":"2008","journal-title":"Clin Pharmacol Ther."},{"key":"key-201381784832-30","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.amjcard.2007.11.065","article-title":"Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome.","volume":"101","author":"Frere C.","year":"2008","journal-title":"Am J Cardiol."},{"key":"key-201381784832-31","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1001\/jama.2011.1703","article-title":"Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease.","volume":"306","author":"Mega JL.","year":"2011","journal-title":"JAMA."},{"key":"key-201381784832-32","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1161\/CIRCULATIONAHA.109.851949","article-title":"Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.","volume":"119","author":"Mega JL.","year":"2009","journal-title":"Circulation."},{"key":"key-201381784832-33","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1001\/jama.2011.1880","article-title":"CYP2C19 genotype, clopidogrel metabolism, platelet function, and cardiovascular events: a systematic review and meta-analysis.","volume":"306","author":"Holmes MV.","year":"2011","journal-title":"JAMA."},{"key":"key-201381784832-34","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1001\/jama.2010.1543","article-title":"Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.","volume":"304","author":"Mega JL.","year":"2010","journal-title":"JAMA."},{"key":"key-201381784832-35","first-page":"88","article-title":"Thienopyridines in the treatment and prevention of cardiovascular diseases. Part II. Clinical pharmacology of clopidogrel.","volume":"49","author":"Preobrazhenskii DV.","year":"2009","journal-title":"Kardiologiia."},{"key":"key-201381784832-36","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1161\/01.CIR.0000106904.80795.35","article-title":"P2Y12 H2 haplotype is associated with peripheral arterial disease: a case-control study.","volume":"108","author":"Fontana P.","year":"2003","journal-title":"Circulation."},{"key":"key-201381784832-37","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1161\/01.STR.0000169922.79281.a5","article-title":"Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease.","volume":"36","author":"Ziegler S.","year":"2005","journal-title":"Stroke."},{"key":"key-201381784832-38","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.thromres.2005.03.001","article-title":"Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease.","volume":"116","author":"Angiolillo DJ.","year":"2005","journal-title":"Thromb Res."},{"key":"key-201381784832-39","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.thromres.2011.12.003","article-title":"ABCB1 C3435T polymorphism and risk of adverse clinical events in clopidogrel treated patients: a meta-analysis.","volume":"129","author":"Luo M.","year":"2012","journal-title":"Thromb Res."},{"key":"key-201381784832-40","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1161\/CIRCINTERVENTIONS.111.965400","article-title":"No association of ABCB1 C3435T genotype with clopidogrel response or risk of stent thrombosis in patients undergoing coronary stenting.","volume":"5","author":"Jaitner J.","year":"2012","journal-title":"Circ Cardiovasc Interv."},{"key":"key-201381784832-41","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1161\/CIRCULATIONAHA.109.885194","article-title":"Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.","volume":"121","author":"Sibbing D.","year":"2010","journal-title":"Circulation."},{"key":"key-201381784832-42","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.2217\/pgs.11.73","article-title":"Impact of genetic variants on post-clopidogrel platelet reactivity in patients after elective percutaneous coronary intervention.","volume":"12","author":"Rideg O.","year":"2011","journal-title":"Pharmacogenomics."}],"container-title":["EuroIntervention"],"original-title":[],"deposited":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T01:02:30Z","timestamp":1563930150000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.pcronline.com\/eurointervention\/62nd_issue\/53"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["EIJV9I3A53"],"URL":"https:\/\/doi.org\/10.4244\/eijv9i3a53","relation":{},"ISSN":["1774-024X"],"issn-type":[{"value":"1774-024X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}